Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0046u-flt3-itd-mrd-ngs-labpmm
    Ask Trek AI about this page

    CPT 0046U: FLT3-ITD MRD Assay by NGS LabPMM

    CPT code 0046U is a Proprietary Laboratory Analyses (PLA) CPT code reported for the FLT3 internal tandem duplication (ITD) minimal residual disease (MRD) assay performed by NGS LabPMM LLC (an Invivoscribe Technologies, Inc. company); it represents a targeted next-generation sequencing laboratory test to detect FLT3-ITD variants for MRD assessment in hematologic malignancies, categorized as a clinical molecular diagnostic laboratory service typically provided in an outpatient or reference laboratory setting.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0046U policy alerts

    Get alerted when payer policies referencing 0046U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 52-year-old patient with a history of acute myeloid leukemia (AML) in apparent morphologic remission presents for molecular surveillance following induction and consolidation therapy. The treating hematologist/oncologist orders a peripheral blood or bone marrow assay to detect minimal residual disease (MRD) targeting FLT3 internal tandem duplication (ITD) variants using a next-generation sequencing (NGS) assay. The specimen is collected in the outpatient infusion center or inpatient hematology unit and sent to LabPMM LLC (an Invivoscribe Technologies, Inc., Company). The laboratory performs the technical FLT3 ITD MRD by NGS test to detect and quantify FLT3 ITD alleles, producing results used by the clinician to guide prognosis, decisions about additional therapy (for example targeted therapy or stem cell transplant planning), and interval surveillance. Typical workflow steps: specimen collection and accessioning, DNA extraction, NGS library preparation and sequencing, bioinformatic analysis for FLT3 ITD detection, laboratory analyst review and technical reporting, and transmission of results to the ordering hematologist/oncologist. Typical sites of service are hospital inpatient labs, hospital outpatient labs, and independent clinical reference laboratories performing specialized molecular pathology testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0046UFLT3 ITD MRD by NGS (Proprietary Laboratory Analyses, specific to LabPMM LLC/Invivoscribe)Primary code reported for the laboratory assay detecting FLT3 ITD variants for MRD assessment.
    81479Unlisted molecular pathology procedureUsed in rare cases for reporting molecular tests not otherwise specified by a PLA code, though 0046U is the specific PLA code for this assay.
    88305Level IV surgical pathology, gross and microscopic exam (not typically used for molecular testing)May be used if a concurrent morphologic bone marrow biopsy interpretation is billed by a pathologist alongside molecular MRD testing.
    81206KRAS gene analysis (example molecular test)Representative of other gene mutation assays that may be ordered alongside FLT3 testing for comprehensive molecular profiling.
    81403Exome or targeted sequencing panel (tiered molecular panel code)Used when broader NGS panels are performed that include FLT3 among multiple genes; indicates relationship when testing is performed as part of multi-gene panels.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0000X
    208M00000X
    171M00000X
    208000000X
    364ST0500X
    207QB0002X
    164W00000X
    305R00000X

    Related ICD-10-CM Codes

    24 rows

    ICD-10-CM CodeDescription
    C83.30Diffuse large B-cell lymphoma, unspecified site
    C92.00Acute myeloblastic leukemia, not having achieved remission
    C92.01Acute myeloblastic leukemia, in remission
    C92.10Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
    C92.11Chronic myeloid leukemia, BCR/ABL-positive, in remission
    C92.20Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission
    C92.21Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission
    C94.6Myelodysplastic disease, not elsewhere classified
    C95.00Acute leukemia of unspecified cell type not having achieved remission
    C95.02Acute leukemia of unspecified cell type, in relapse

    Showing 1–10 of 24

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.